Rabbit Recombinant Monoclonal Ezrin antibody. Suitable for IHC-P, WB and reacts with Human samples.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA
IHC-P | IP | Flow Cyt | WB | ICC/IF | |
---|---|---|---|---|---|
Human | Tested | Not recommended | Not recommended | Tested | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/250 - 1/500 | Notes Perform heat-mediated antigen retrieval before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/10000 - 1/50000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Select an associated product type
Probably involved in connections of major cytoskeletal structures to the plasma membrane. In epithelial cells, required for the formation of microvilli and membrane ruffles on the apical pole. Along with PLEKHG6, required for normal macropinocytosis.
VIL2, EZR, Ezrin, Cytovillin, Villin-2, p81
Rabbit Recombinant Monoclonal Ezrin antibody. Suitable for IHC-P, WB and reacts with Human samples.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Ezrin also known as cytovillin or villin-2 is a protein belonging to the ezrin-radixin-moesin (ERM) family. It is approximately 81 kDa in molecular weight. Ezrin plays a critical role in linking the actin cytoskeleton to the plasma membrane. This interaction occurs through its ability to bind to membrane proteins and phospholipids facilitating structural support and signal transduction. Ezrin is widely expressed in epithelial tissues but it also occurs in other cell types such as lymphocytes and osteoclasts.
Ezrin functions as a membrane-microfilament linker and is essential for maintaining cell shape adhesion and motility. It is an integral component of many cellular structures including microvilli and ruffles. Ezrin’s activity often involves forming complexes with other proteins such as EBP50 and F-actin which are fundamental for its role in cellular morphogenesis. These interactions allow ezrin to regulate membrane surface structure and cell surface organization.
Ezrin participates in various signaling pathways that are essential for cell migration and invasion. One key pathway is the Rho family of GTPases which regulates actin cytoskeleton dynamics. Ezrin interacts with proteins like Rho-associated kinase (ROCK) that influence cell contraction and motility. Additionally ezrin is involved in the MAPK/ERK pathway which influences cell growth and survival by interacting with other signaling molecules.
Ezrin shows significant relevance to cancer progression and metastasis particularly in conditions like osteosarcoma. Ezrin overexpression correlates with increased metastatic potential and poor clinical outcomes. It also has implications in allergic diseases due to its role in immune cell function. In these contexts ezrin interacts with SRC family kinases which are important for transmitting signals from cell-surface receptors to downstream pathways influencing disease development and progression.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Lanes 1- 2: Merged signal (red and green). Green - ab133297 observed at 75 kDa. Red - Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) observed at 37 kDa.
ab133297 was shown to react with Ezrin in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line was used. Wild-type HeLa and EZR knockout HeLa cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab133297 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) overnight at 4°C at a 1 in 1000 Dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-Ezrin antibody [EPR803] (ab133297) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: EZR knockout HeLa cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 69 kDa
Observed band size: 75 kDa
Immunohistochemical analysis of paraffin-embedded Human kidney tissue labelling Ezrin with ab133297 at 1/250 dilution.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
This data was developed using the same antibody clone in a different buffer formulation (ab133297).
Lanes 1 - 4: Merged signal (red and green). Green - ab133297 observed at 75 kDa. Red - loading control, ab18058, observed at 130 kDa.
ab133297 was shown to specifically react with Ezrin in wild-type HAP1 cells as signal was lost in Ezrin knockout cells. Loss of signal was observed when knockout cell line was used. Wild-type and Ezrin knockout samples were subjected to SDS-PAGE. ab133297 and ab18058 (Mouse anti-Vinculin loading control) were incubated overnight at 4°C at 1/10000 dilution and 1/20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-Ezrin antibody [EPR803] (ab133297) at 1/10000 dilution
Lane 1: Wild-type HAP1 whole cell lysate at 20 µg
Lane 2: Ezrin knockout HAP1 whole cell lysate at 20 µg
Lane 3: HeLa whole cell lysate at 20 µg
Lane 4: HCT116 whole cell lysate at 20 µg
Predicted band size: 69 kDa
Immunohistochemical analysis of paraffin-embedded Human transitional cell carcinoma tissue labelling Ezrin with ab133297 at 1/250 dilution.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
All lanes: Western blot - Anti-Ezrin antibody [EPR803] (ab133297) at 1/10000 dilution
Lane 1: HeLa cell lysate at 10 µg
Lane 2: 293T cell lysate at 10 µg
Lane 3: A549 cell lysate at 10 µg
Lane 4: SH-SY5Y cell lysate at 10 µg
All lanes: Goat Anti-rabbit HRP at 1/2000 dilution
Predicted band size: 69 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com